TITLE

Coxib medications to be handled with care

AUTHOR(S)
Misak, Aleksandra
PUB. DATE
February 2005
SOURCE
CMAJ: Canadian Medical Association Journal;2/1/2005, Vol. 172 Issue 3, p330
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the health risks of coxib medications or the cyclooxygenase-2 (COX-2) inhibitors. Increase in the risk of myocardial infarction and cerebrovascular accident in patients taking celecoxib; Indication of COX-2 inhibitors; Logic of using COX-2 inhibitors as a replacement for nonsteroidal anti-inflammatory agents.
ACCESSION #
15784052

 

Related Articles

  • Renal effects of cyclooxygenase inhibitors in volume-depleted dogs. Brooks, David P.; Adams, Jerry; DePalma, P. Dennis; Webb, Edward F.; Palmer, Robert H.; Griswold, Don E. // Inflammopharmacology;2000, Vol. 8 Issue 1, p69 

    Objective: The objective of this study was to investigate the renal effects of celecoxib, a cyclooxygenase-2 (COX-2) specific nonsteroidal anti-inflammatory drug (NSAID). Subjects and treatment: Six volume-depleted, conscious, chronically instrumented dogs received four treatments using a...

  • Celecoxib and rofecoxib. Moore, Paul A.; Hersh, Elliot V. // Journal of the American Dental Association (JADA);Apr2001, Vol. 132 Issue 4, p451 

    Reports on the development of the nonsteroidal anti-inflammatory drugs (NSAID), celecoxib and rofecoxib, to limit the adverse effects seen after chronic use of NSAID. Cyclo-oxygenase mechanism; Specific cyclo-oxygenase 2 inhibitors; Decrease in the antihypertensive effects of...

  • Celecoxib. O'Rourke, Maureen E. // Clinical Journal of Oncology Nursing;May/Jun2000, Vol. 4 Issue 3, p143 

    Provides information on Celecoxib, a nonsteroidal anti-inflammatory drug and a cyclooxygenase-2-inhibitor. Indications of the drug; Effect of the drug on blood count; Precautions for the drug.

  • New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). Cotter, Jill; Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;5/10/2005, Vol. 172 Issue 10, p1299 

    Presents a study which investigated cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. Degree of inhibition of cyclooxygenase 2 relative to cyclooxygenase 1 for various nonsteroidal anti-inflammatory agents; Advice on the use of celecoxib.

  • COX-2 inhibitor drugs. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p201 

    An encyclopedia entry for "COX-2 inhibitor drugs" is presented. They refer to a group of nonsteroidal anti-inflammatory drugs (NSAIDs) which are less likely to cause stomach irritation. Celecoxib is one example of a COX-2 inhibitor drug.

  • CV disorder risks extend beyond COX-2-selectivity of NSAIDs.  // Reactions Weekly;9/22/2007, Issue 1170, p3 

    The article deals with studies on the association of the use of NSAIDs with increased risk of stroke and myocardial infarction (MI), regardless of COX-2-selectivity. The first study estimated the relative risk of thrombotic and haemorrhagic strokes in patients with arthritis who had received...

  • Temporal Relationship between Use of NSAIDs, Including Selective COX-2 Inhibitors, and Cardiovascular Risk. Motsko, Stephen P.; Rascati, Karen L.; Busti, Anthony J.; Wilson, James P.; Barner, Jamie C.; Lawson, Kenneth A.; Worchel, Jason // Drug Safety;2006, Vol. 29 Issue 7, p621 

    BACKGROUND AND OBJECTIVE: The search for NSAIDs with less gastrointestinal toxicity led to the introduction of the selective cyclo-oxygenase-2 (COX-2) inhibitors. However, following their introduction into the market, concerns have developed regarding their safety, particularly their...

  • Study evaluates aspirin comedication rates among long-term COX-2 inhibitor users.  // Formulary;Sep2004, Vol. 39 Issue 9, p434 

    Evaluates aspirin comedication rates among long-term COX-2 inhibitor users. Lack of difference in gastrointestinal infection ulcer complication rates between celecoxib and nonselective NSAID; Percentage of comedication with over-the-counter pain relievers.

  • COX-2 controversy: where are we and where do we go from here? Khanna, Dinesh; Khanna, Puja P.; Furst, Daniel E. // Inflammopharmacology;2005, Vol. 13 Issue 4, p395 

    Much has been written in the last few months on the association between the cyclooxygenase-2 (COX-2)-selective inhibitors and cardiovascular events. We summarize the randomized controlled studies of different COX-2 inhibitors that led to rofecoxib withdrawal, provide evidence on the differences...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics